Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01873326 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors
A Phase 2 study of Germ Cell Tumors, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
- 13
- Study locations
NCT01873326 is a Phase 2 study of Germ Cell Tumors that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 92 participants, above the 63-participant average among 3 other Germ Cell Tumors trials with a reported enrollment target (46% higher). The trial reports 13 study locations across 7 states.
The verdict
NCT01873326, a Phase 2 study of Germ Cell Tumors, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to learn about the safety and effectiveness of two different drug combinations in patients who have intermediate- and poor-risk germ cell tumors (GCT). One combination of drugs, paclitaxel, ifosfamide and cisplatin (TIP), is experimental. The other combination of drugs, bleomycin, etoposide and cisplatin (BEP), is the standard of care treatment for intermediate- and poor-risk germ cell tumors. However, BEP does not cure every patient and therefore newer treatments are needed.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Mesna
- DRUG Paclitaxel
- DRUG Ifosfamide
- DRUG Bleomycin
Study Locations (13)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Cancer Center - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen (Follow-up Only) - Montvale
California
- University of Southern California - Los Angeles
- Stanford University Medical Center - Stanford
Illinois
- University of Chicago - Chicago
Minnesota
- Mayo Clinic - Rochester
North Carolina
- University of North Carolina - Chapel Hill
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2013-06 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01873326
The ClinicalTrials.gov registry entry for NCT01873326 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 63-participant average among 3 other Germ Cell Tumors trials with a reported enrollment target (46% higher). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Germ Cell Tumors appearing as the primary indexed condition, and to 5 interventions - of which Cisplatin is the first listed.
NCT01873326 reports 13 study locations spanning 7 distinct geographic areas - top geographies include New York, New Jersey, California.
Frequently Asked Questions
What is clinical trial NCT01873326 about?
NCT01873326 is a clinical study titled "Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors". The purpose of this study is to learn about the safety and effectiveness of two different drug combinations in patients who have intermediate- and poor-risk germ cell tumors (GCT). One combination of drugs, paclitaxel, ifosfamide and cisplatin (TIP), is experimental. The other combination of drugs, ...
What is the current status of trial NCT01873326?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2013-06. Estimated completion is 2026-06.
What conditions does trial NCT01873326 study?
This clinical trial studies the following conditions: Germ Cell Tumors.
What interventions are being tested in trial NCT01873326?
The interventions under investigation include: Cisplatin (DRUG), Mesna (DRUG), Paclitaxel (DRUG), Ifosfamide (DRUG), Bleomycin (DRUG).
Who is sponsoring clinical trial NCT01873326?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01873326 being conducted?
This trial has 13 study locations across California, Illinois, Minnesota, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Germ Cell Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
RECRUITING · Phase 1
-
Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
COMPLETED · Phase 3
-
Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.